The Pharmacological Basis of Therapeutics A Textbook of Pharmacology, Toxicology and Therapeutics for Physicians and Medical Students. By Prof. Louis Goodman and Prof. Alfred Gilman. Pp. xiii + 1383. (New York: The Macmillan Company, 1941.) 50s. net.

The Pharmacological Basis of Therapeutics

In this paper, we define and explore proofs of retrievability (PORs). A POR scheme enables an archive or back-up service (prover) to produce a concise proof that a user (verifier) can retrieve a target file F, that is, that the archive retains and reliably transmits file data sufficient for the user to recover F in its entirety.A POR may be viewed as a kind of cryptographic proof of knowledge (POK), but one specially designed to handle a large file (or bitstring) F. We explore POR protocols here in which the communication costs, number of memory accesses for the prover, and storage requirements of the user (verifier) are small parameters essentially independent of the length of F. In addition to proposing new, practical POR constructions, we explore implementation considerations and optimizations that bear on previously explored, related schemes.In a POR, unlike a POK, neither the prover nor the verifier need actually have knowledge of F. PORs give rise to a new and unusual security definition whose formulation is another contribution of our work.We view PORs as an important tool for semi-trusted online archives. Existing cryptographic techniques help users ensure the privacy and integrity of files they retrieve. It is also natural, however, for users to want to verify that archives do not delete or modify files prior to retrieval. The goal of a POR is to accomplish these checks without users having to download the files themselves. A POR can also provide quality-of-service guarantees, i.e., show that a file is retrievable within a certain time bound.

PORs: Proofs of Retrievability for Large Files

Despite the increasing usage of cloud computing, there are still issues unsolved due to inherent problems of cloud computing such as unreliable latency, lack of mobility support and location-awareness. Fog computing can address those problems by providing elastic resources and services to end users at the edge of network, while cloud computing are more about providing resources distributed in the core network. This survey discusses the definition of fog computing and similar concepts, introduces representative application scenarios, and identifies various aspects of issues we may encounter when designing and implementing fog computing systems. It also highlights some opportunities and challenges, as direction of potential future work, in related techniques that need to be considered in the context of fog computing.

https://www.cs.wm.edu/~liqun/paper/mobidata15-fog.pdf

A Survey of Fog Computing: Concepts, Applications and Issues

Review: Intrusion detection system: A comprehensive review

Fog Computing is a paradigm that extends Cloud computing and services to the edge of the network Similar to Cloud, Fog provides data, compute, storage, and application services to end-users In this article, we elaborate the motivation and advantages of Fog computing, and analyse its applications in a series of real scenarios, such as Smart Grid, smart traffic lights in vehicular networks and software defined networks We discuss the state-of-the-art of Fog computing and similar work under the same umbrella Security and privacy issues are further disclosed according to current Fog computing paradigm As an example, we study a typical attack, man-in-the-middle attack, for the discussion of security in Fog computing We investigate the stealthy features of this attack by examining its CPU and memory consumption on Fog device

https://annals-csis.org/Volume_2/pliks/503.pdf

The Fog computing paradigm: Scenarios and security issues

https://romisatriawahono.net/lecture/rm/survey/network%20security/Modi%20-%20Intrusion%20Detection%20in%20Cloud%20-%202013.pdf

Review: A survey of intrusion detection techniques in Cloud

Background & aims Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common clinico-pathological conditions that affect millions of patients worldwide. In this study, the efficacy of saroglitazar, a novel PPARα/γ agonist, was assessed in models of NAFLD/NASH. Methods & results HepG2 cells treated with palmitic acid (PA;0.75 mM) showed decreased expression of various antioxidant biomarkers (SOD1, SOD2, glutathione peroxidase and catalase) and increased expression of inflammatory markers (TNFα, IL1β and IL6). These effects were blocked by saroglitazar, pioglitazone and fenofibrate (all tested at 10μM concentration). Furthermore, these agents reversed PA-mediated changes in mitochondrial dysfunction, ATP production, NFkB phosphorylation and stellate cell activation in HepG2 and HepG2-LX2 Coculture studies. In mice with choline-deficient high-fat diet-induced NASH, saroglitazar reduced hepatic steatosis, inflammation, ballooning and prevented development of fibrosis. It also reduced serum alanine aminotransferase, aspartate aminotransferase and expression of inflammatory and fibrosis biomarkers. In this model, the reduction in the overall NAFLD activity score by saroglitazar (3 mg/kg) was significantly more prominent than pioglitazone (25 mg/kg) and fenofibrate (100 mg/kg). Pioglitazone and fenofibrate did not show any improvement in steatosis, but partially improved inflammation and liver function. Antifibrotic effect of saroglitazar (4 mg/kg) was also observed in carbon tetrachloride-induced fibrosis model. Conclusions Saroglitazar, a dual PPARα/γ agonist with predominant PPARα activity, shows an overall improvement in NASH. The effects of saroglitazar appear better than pure PPARα agonist, fenofibrate and PPARγ agonist pioglitazone.

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.13634

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

A state-of-the-art survey on recommendation system and prospective extensions

Blockchain state-of-the-art: architecture, use cases, consensus, challenges and opportunities

Background Obesity, diabetes and dyslipidemica are the key pathogenic stimulus that enhances progression of Non-Alcoholic Fatty Liver Disease (NAFLD). Coagonist of Glucagon Like- Peptide-1 (GLP-1) Receptor (GLP-1R) and Glucagon Receptor (GCGR) are being evaluated for obesity and diabetes. GLP-1 analogs have shown to reverse diabetes and obesity. Glucagon treatment reduces lipids after acute and chronic treatment. Objective In this study, we have investigated the effect of co-agonist on the prevention of NAFLD induced by long-term feeding of High Fat Diet (HFD). Method We have used HFD to induce NAFLD after chronic feeding in mice. Co-agonist treatment (150 µg.kg-1, s.c.) was initiated with induction of HFD, which was continued for 40 weeks. Body weight, food intake, glucose homeostasis, lipid profile, inflammatory and fibrotic markers were assessed at the end of treatment. Results Co-agonist treatment prevented body weight gain, glucose intolerance and insulin resistance. Treatment with co-agonist reduced NEFA, increased FGF21 and adiponectin levels. Co-agonist increased glycerol release and energy expenditure, while decreased respiratory quotient. Co-agonist reduced lipids in circulation and liver. Expression of SREBP-1C, SCD-1, ACC and FAS were decreased, while ACOX1 and CPT1 were increased after co-agonist treatment. Inflammatory cytokine TNF-α and IL-6 in plasma and expression of MCP-1, TGF-s, MMP-9, TNF-α, TIMP-1, α-SMA, and COL1A1 were decreased after co-agonist treatment. Plasma transaminases, hepatic TBARS, hepatic hydroxyproline and relative liver weight were suppressed after co-agonist treatment. Fat accumulation, inflammation and fibrosis were reduced in histological assessment of liver in co-agonist treated animals. Conclusion Co-agonist prevented development of HFD-induced NAFLD by ameliorating obesity, diabetes, inflammation and fibrosis.

Hiren Patel

Papers

Review: A survey of intrusion detection techniques in Cloud

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

A state-of-the-art survey on recommendation system and prospective extensions

Blockchain state-of-the-art: architecture, use cases, consensus, challenges and opportunities

Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease